Table 1.
Baseline characteristics of each patient.
| Patient number |
||||||
|---|---|---|---|---|---|---|
| N=5 | 1 | 2 | 3 | 4 | 5 | |
| Age, y | 66 (50.5-77.5) | 76 | 68 | 74 | 33 | 79 |
| Male | 4 (80.0%) | Male | Female | Male | Male | Male |
| Caucasian | 5 (100.0%) | Yes | Yes | Yes | Yes | Yes |
| Body mass index, kg/m2 | 25.3 (22.0-26.7) | 27.3 | 26.0 | 25.3 | 18.8 | 25.2 |
| Ischemic cardiomyopathy | 3 (60.0%) | Yes | Yes | Yes | No | No |
| Comorbidities | ||||||
| Hypertension | 3 (60.0%) | Yes | Yes | Yes | No | No |
| Dyslipidemia | 3 (60.0%) | Yes | Yes | Yes | No | No |
| Diabetes mellitus | 2 (40.0%) | Yes | No | Yes | No | No |
| Atrial tachycardia flutter or fibrillation | 3 (60.0%) | No | Yes | Yes | No | Yes |
| Coronary artery disease | 3 (60.0%) | Yes | Yes | Yes | No | No |
| Chronic kidney disease, stage 3-4 | 4 (80.0%) | Yes | Yes | Yes | No | Yes |
| Medical and device therapy | ||||||
| Beta blocker | 5 (100.0%) | Yes | Yes | Yes | Yes | Yes |
| ACE inhibitor/ARB/ARNI | 5 (100.0%) | Sacubitril-Valsartan | Lisinopril | Sacubitril-Valsartan | Sacubitril-Valsartan | Valsartan |
| Aldosterone antagonist | 5 (100.0%) | Yes | Yes | Yes | Yes | Yes |
| Loop diuretic | 5 (100.0%) | Yes | Yes | Yes | Yes | Yes |
| Furosemide baseline daily dosage, mg | 40.0 (30.0-60.0) | 40 | 40 | 40 | 20 | 80 |
| ICD or CRT-D device | 5 (100.0%) | ICD | ICD | ICD | ICD | CRT-D |
| Time from device to CM implant, days | 1642 (353-4682) | 290 | 416 | 3869 | 1642 | 5495 |
| Laboratory analyses | ||||||
| Hemoglobin, g/dL | 13.4 (11.8-14.6) | 14.9 | 14.3 | 13.4 | 12.6 | 10.9 |
| Creatinine, mg/dL | 1.4 (1.3-1.4) | 1.4 | 1.4 | 1.4 | 1.2 | 1.3 |
| GFR, mL/min per 1.73 m2 | 50 (42.0-63.5) | 47 | 37 | 50 | 75 | 52 |
| NT-proBNP, pg/mL | 3157 (1063-6086) | 357 | 1769 | 3157 | 5393 | 8219 |
| Echocardiographic parameters | ||||||
| Left ventricular end-diastolic volume, mL | 183 (127.5-345.5) | 106 | 149 | 188 | 183 | 503 |
| Left ventricular end-systolic volume, mL | 121 (90.0-254.5) | 73 | 107 | 133 | 121 | 376 |
| LVEF, % | 29 (26.5-32.0) | 31 | 28 | 29 | 33 | 25 |
| GLS, % | -7.2 (-8.2-6.4) | -8.5 | -7.2 | -7.0 | -6.2 | -6.8 |
| Left atrium volume, ml/m2 | 43 (31.5-64.0) | 22 | 41 | 66 | 43 | 62 |
| TAPSE, mm | 18 (12.0-20.5) | 14 | 20 | 21 | 18 | 10 |
ACE: angiotensin-converting enzyme; ARA: angiotensin receptor blocker; ARNI: angiotensin receptor/neprilysin inhibitor; ICD: implantable cardioverter defibrillator; CRT (cardiac resynchronization therapy); CM: CardioMEMS; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; GLS: global longitudinal strain; TAPSE: tricuspid annular plane systolic excursion.
Data expressed as median (interquartile range).